

**ICCVAM/NICEATM/ECVAM Scientific Workshop on Alternative Methods  
to Refine, Reduce, and Replace the Mouse LD<sub>50</sub> Assay For Botulinum Toxin Testing  
(November 13 - 14, 2006)**

***Selected References***

*Session 1: Overview of Public Health Needs for Botulinum Toxin Testing and Regulatory Requirements*

Hicks RP, Hartell MG, Nichols DA, Bhattacharjee AK, van Hamont JE, Skillman DR. 2005. The medicinal chemistry of botulinum, ricin, and anthrax toxins. *Curr Med Chem.* 12:667-690.

Sharma SK, Whiting RC. 2005. Methods for detection of Clostridium botulinum toxin in foods. *J Food Protect.* 68:1256-1263.

*Session 2: Current Understanding and Knowledge Gaps for Botulinum Toxin*

Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER. 2006. SV2 is the protein receptor for botulinum neurotoxin A. *Science.* 312:592-596.

Jahn R. 2006. Neuroscience. A neuronal receptor for botulinum toxin. *Science.* 312:540-541.

Ravichandran E, Gong Y, Al Saleem FH, Ancharski DM, Joshi SG, Simpson LL. 2006. An initial assessment of the systemic pharmacokinetics of botulinum toxin. *J Pharmacol Exper Ther.* 318:1343-1351.

Dressler D, Saberi FA, Barbosa ER. 2005. Botulinum toxin mechanisms of action. *Arquivos de Neuro-Psiquiatria.* 63:180-185.

Hicks RP, Hartell MG, Nichols DA, Bhattacharjee AK, van Hamont JE, Skillman DR. 2005. The medicinal chemistry of botulinum, ricin and anthrax toxins. *Curr Med Chem.* 12:667-690.

Simpson LL. 2004. Identification of the major steps in botulinum toxin action. *Ann Rev Pharmacol Toxicol.* 44:167-193.

*Session 3: Potential Replacement of Animal Use for Botulinum Toxin Potency Testing*

Session 3A: Endopeptidase Assays

Kalb SR, Moura H, Boyer AE, McWilliams LG, Pirkle JL, Barr JR. 2006. The use of Endopep-MS for the detection of botulinum toxins A, B, E, and F in serum and stool samples. *Analyt Biochem.* 351:84-92.

Barr JR, Moura H, Boyer AE, Woolfitt AR, Kalb SR, Pavlopoulos A, McQuilliams LG, Schmidt JG, Martinez RA, Ashley DL. 2005. Botulinum neurotoxin detection and differentiation by mass spectrometry. *Emerg Infect Dis.* 11:1578-1583.

Gilmore MA, Williams D, Steward LE, Okawa Y, Weber JA, Verhagen MF, Aoki KR. 2005. A coupled FRET-fluorescence polarization assay of BoNT proteolytic activity with a fully recombinant substrate. Abstract 35. Presented at Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins International Conference (Toxins 2005), June 23-25, 2005, Denver, CO.

Mangru S, Bentz BL, Davis TJ, Desai N, Stabile PJ, Schmidt JJ, Millard CB, Bavari S, Kodukula K. 2005. Integrated bioassays in microfluidic devices: botulinum toxin assays. *J Biomol Screen*. 10:788-794.

Parpura V, Chapman ER. 2005. Detection of botulinum toxins: Micromechanical and fluorescence-based sensors. *Croat Med J*. 46:491-497.

Steward LE, Fernandez-Salas E, Garay PE, Malik S, Lewis RO, Aoki KR. 2005. A sensitive call-based fluorescence resonance energy transfer (FRET) assay for botulinum neurotoxins. Abstract 76. Presented at Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins International Conference (Toxins 2005), June 23-25, 2005, Denver, CO.

Williams D, Steward LE, Gilmore MA, Okawa Y, Webber JA, Aoki KR. 2005. GFP-SNAP25 fluorescence release assay of BoNT proteolytic activity. Abstract 83. Presented at Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins International Conference (Toxins 2005), June 23-25, 2005, Denver, CO.

Gaines Das RE, Heath AB, Martin H, Sesardic D. 1999. Validation of in vitro assays for botulinum toxin: a case study. *Developments in Biological Standardization*. 101:267-276.

Wictome M, Newton K, Jameson K, Hallis B, Dunnigan P, Mackay E, Clarke S, Taylor R, Gaze J, Foster K, Shone C. 1999. Development of an in vitro bioassay for *Clostridium botulinum* type B neurotoxin in foods that is more sensitive than the mouse bioassay. *App Environ Microbiol*. 65:3787-3792.

Sesardic D, Corran PH, McLellan K, Feavers IM, Ekong TAN. 1997. In vitro assays for estimating the activity of therapeutic preparations of botulinum toxin. In: *Animal Alternatives, Welfare And Ethics: Proceedings of the 2nd World Congress on Alternatives and Animal Use in the Life Sciences*, (van Zutphen LFM and Balls M, eds). Elsevier Science Ltd. 1033-1038.

Ekong T, Gee C, Blasi J, Sesardic D. 1997. An alternative bioassay for botulinum neurotoxin type A based on its endopeptidase activity. In: *Animal Alternatives, Welfare And Ethics: Proceedings of the 2nd World Congress on Alternatives and Animal Use in the Life Sciences*, (van Zutphen LFM and Balls M, eds). Elsevier Science Ltd. 1039-1040.

### Session 3B: Cell-Based Assays

Ferracci G, Miquelis R, Kozaki S, Seagar M, Leveque C. 2005. Synaptic vesicle chips to assay botulinum neurotoxins. *Biochem J*. 391:659-666.

- Parpura V, Chapman E. 2005. Detection of botulinum toxin: Micromechanical and fluorescence-based sensors. *Croat Med J.* 46:491-497.
- Sheridan RE, Smith TJ, Adler M. 2005. Primary cell culture for evaluation of botulinum neurotoxin antagonists. *Toxicon.* 45:377-382.
- Dong M, Tepp WH, Johnson EA, Chapman ER. 2004. Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. *Proc Natl Acad Sci.* 101:14701-14706.
- Hall YHJ, Chaddock JA, Moulds HJ, Kirby ER, Alexander FCG, Marks JD, Foster KA. 2004. Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies. *J Immunol Meth.* 288:55-60.
- Keller J, Cai F, Neale EA. 2004. Uptake of botulinum neurotoxin into cultured neurons. *Biochem.* 43:526-532.
- Purkiss JR, Friis LM, Doward S, Quinn CP. 2001. Clostridium botulinum neurotoxins act with a wide range of potencies on SH-SY5Y human neuroblastoma cells. *NeuroToxicol.* 22:447-453.
- Ekong TAN, Feavers IM, Sesardic D. 1997. Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. *Microbiol.* 143:3337-3347.
- Foran P, Lawrence GW, Shone CC, Foster KA, Dolly JO. 1996. Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: Correlation with its blockade of catecholamine release. *Biochem.* 35:2630-2636.
- Tamori Y, Hashiramoto M, Araki S, Kamata Y, Takahashi M, Kozaki S, Kasuga M. 1996. Cleavage of vesicle-associated membrane protein (VAMP)-2 and cellubrevin on GLUT4-containing vesicles inhibits the translocation of GLUT4 in 3T3-L1 adipocytes. *Biochem Biophys Res Comm.* 220:740-745.
- Williamson LC, Halpern JL, Montecucco C, Brown JE, Neale EA. 1996. Clostridial neurotoxins and substrate proteolysis in intact neurons. *J Biol Chem.* 271:7694-7699.
- Boyd RS, Duggan MJ, Shone CG, Foster KA. 1995. The effect of botulinum neurotoxins on the release of insulin from the insulinoma cell lines HIt-15 and RINm5F. *J Biol Chem.* 270:18216-18218.
- Poulain B, Mochida S, Weller U, Hogy B, Habermann E, Wadsworth JDF, Shone CC, Dolly JO, Tauc L. 1991. Heterologous combination of heavy and light chain from botulinum neurotoxin A and tetanus toxin inhibit neurotransmitter release in Aplysia. *J Biol Chem.* 266:9580-9585.

*Session 4: Refinement (Less Pain and Distress) of Animal Use for Botulinum Toxin Potency Testing*

Session 4A: Refinement: Using *Ex Vivo* Assays to Avoid Pain and Distress in Botulinum Testing

Jones RGA. 2006. Phrenic Nerve Hemidiaphragm Assay: In vitro (ex vivo) assessment of botulinum neurotoxicity (Standard Operating Procedure). National Institute for Biological Standards and Control.

Session 4B: Refinement: Alternative *In Vivo* Botulinum Assays that Do Not Require Death as an Endpoint

Jones RGA, Alsop TA, Hull R, Tierney R, Rigsby P, Holley J, Sesardic D. 2006. Botulinum type A toxin neutralisation by specific IgG and its fragments: A comparison of mouse systemic toxicity and local flaccid paralysis assays. *Toxicon*. 48:246-254.

Aoki KR. 2002. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical and models of muscle weakening efficacy and systemic safety. *Toxicon*. 40:923-928.

Aoki KR. 2001. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. *Toxicon*. 39:1815-1820.

Sesardic D, McLellan K, Ekong TAN, Gaines Das, R. 1996. Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin. *Pharmacol Toxicol*. 78:283-288.

Takahashi M, Kameyama S, Sakaguchi G. 1990. Assay in mice for low levels of Clostridium botulinum toxin. *Int J Food Microbiol*. 11:271-278.

Session 4C: Refinement: Potential Use of Non-Lethal Endpoints in Botulinum LD<sub>50</sub> Testing to Minimize Pain and Distress

Keller JE. 2006. Recovery from botulinum neurotoxin poisoning in vivo. *Neuroscience*. 139:629-637.

Lindstrom M, Korkeala H. 2006. Laboratory diagnostics of botulism. *Clin Microbiol Rev*. 19:298-314.

Taysse L, Daulon S, Calvet JH, Delamanche S, Hilaire D, Bellier B, Breton P. 2005. Induction of acute lung injury after intranasal administration of toxin botulinum A complex. *Toxicol Pathol*. 33:336-342.

Stokes WS. 2002. Humane endpoints for laboratory animals used in regulatory testing. *ILAR J*. 2(Suppl):S31-S38.

Calver G, Gavieres J, Shakarchi N, Thibert P. 2000. Enhancing animal well-being through refinement by establishing non-lethal endpoints in regulatory assays of certain biologicals. (Abstract). Presented at the Third World Congress on Alternatives and Animal Use in the Life Sciences, August 29-September 2, 1999, Bologna, Italy. *ATLA* 27:373.

*Session 5: Reduction of Animal Use for In Vivo Botulinum Testing*

Sesardic D, Leung T, Das RG. 2003. Role for standards in assays of botulinum toxins: International collaborative study of three preparations of botulinum type A toxin. *Biologicals*. 31:265-276.

Pearce LB, Borodic GE, First ER, MacCallum RD. 1994. Measurement of botulinum toxin activity: Evaluation of the lethality assay. *Toxicol App Pharmacol*. 128:69-77.

***[This Page Intentionally Left Blank]***